Kazia Therapeutics Limited (Nasdaq: KZIA), a clinical-stage oncology company advancing therapies to reprogram cancer biology and overcome treatment resistance, announces the in-licensing of a first-in ...
Kazia Therapeutics (NASDAQ: KZIA), a clinical-stage oncology company developing differentiated therapies for cancers with high unmet need, today announced the appointment of Dr. Sudha Rao as Chief ...
Life Biosciences, a Boston longevity biotech co-founded by Harvard genetics professor David Sinclair, has locked down an $80 ...
India, April 13 -- Life Biosciences, a clinical-stage biotechnology company focused on reversing diseases of aging, has ...
Yuancheng Ryan Lu could barely breathe while he waited for his labmate to adjust the microscope focus. On the slide in front ...
Lactate, once considered a metabolic waste product, is now recognized as a key regulator of cellular homeostasis and disease progression. In gynecological malignancies-including ovarian, cervical, and ...
Scientists at Life Biosciences are preparing to begin testing partial reprogramming in people. It will mark the first time ...
Endogenous Retroviruses (ERVs), relics from ancient viral infections, form a significant part of vertebrate genomes, including humans, where they constitute ...
A startup cofounded by a renowned Harvard geneticist has taken a step toward cracking the human body’s biological breakdown by securing FDA approval to test its cutting-edge gene therapy on humans.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results